Arbutus Biopharma (ABUS) Other Working Capital Changes (2013 - 2026)
Arbutus Biopharma (ABUS) posted Other Working Capital Changes of $195000.0 for Q1 2026, up 102.03% sequentially from -$9.6 million in Q2 2025, and up 124.01% YoY from $87047.8 in Q1 2025.
Arbutus Biopharma (ABUS) Other Working Capital Changes (2013 - 2026) Analysis & Trends
Arbutus Biopharma has reported Other Working Capital Changes for 14 years, with the latest figure at $195000.0 in Q1 2026.
- Quarterly Other Working Capital Changes fell 123.8% year-over-year to -$649000.0 in Q4 2018, while the trailing twelve-month figure through Sep 2019 was -$649000.0 (down 202.37% YoY) and the FY2018 annual result came in at -$2.7 million, down 200.55% from the prior year.
- Other Working Capital Changes fell to -$649000.0 in Q4 2018 per ABUS's latest filing, from -$325000.0 in the prior quarter.
- Over five years, Other Working Capital Changes peaked at $2.7 million in Q4 2017 and troughed at -$6.7 million in Q3 2017.
- A 5-year average of -$49733.3 and a median of -$1.2 million in 2024 frame the typical range for Other Working Capital Changes.
- The widest YoY moves for Other Working Capital Changes: up 4432.09% in 2022, down 2550.24% in 2022.
- Over 2 years, Other Working Capital Changes stood at $2.7 million in 2017, then tumbled by 123.8% to -$649000.0 in 2018.
- According to Business Quant data, Other Working Capital Changes over the past three periods registered -$649000.0, -$325000.0, and -$746000.0 for Q4 2018, Q3 2018, and Q2 2018 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Arbutus Biopharma | 922.95 Mn | 830.33 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -215,000.00 |
| Jun 30, 2026 | -215,000.00 |
| Jun 30, 2026 | -215,000.00 |
| Mar 31, 2026 | 195,000.00 |
| Mar 31, 2026 | 195,000.00 |
| Mar 31, 2026 | 195,000.00 |
| Jun 30, 2025 | -9.62 Mn |
| Jun 30, 2025 | -9.62 Mn |
| Jun 30, 2025 | -9.62 Mn |
| Mar 31, 2025 | -812,000.00 |
| Mar 31, 2025 | -812,000.00 |
| Mar 31, 2025 | -812,000.00 |
| Dec 31, 2024 | -1.15 Mn |
| Dec 31, 2024 | -1.15 Mn |
| Dec 31, 2024 | -1.15 Mn |
| Sep 30, 2024 | -388,000.00 |
| Sep 30, 2024 | -388,000.00 |
| Sep 30, 2024 | -388,000.00 |
| Jun 30, 2024 | -513,000.00 |
| Jun 30, 2024 | -513,000.00 |